Multiple endocrine neoplasia, type 2

Search Trials
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Status:
Active, not recruiting
Last Changed:
Jun 7, 2018
First Changed:
Sep 8, 2007
Disease(s):
Medullary Thyroid Carcinoma
Intervention(s):
Vandetanib
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Status:
Completed
Last Changed:
May 4, 2018
First Changed:
Jan 1, 1970
Disease(s):
Medullary Thyroid Carcinoma
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Status:
Active, not recruiting
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Hereditary Thyroid Gland Medullary Carcinoma
Intervention(s):
Laboratory Biomarker AnalysisPharmacological StudySorafenib Tosylate
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Status:
Withdrawn
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Functional Pancreatic Neuroendocrine Tumor
Intervention(s):
CapecitabineTemozolomideVeliparibPharmacological StudyLaboratory Biomarker Analysis
Familial Investigations of Childhood Cancer Predisposition
Status:
Recruiting
Last Changed:
Jan 1, 1970
First Changed:
Oct 2, 2017
Disease(s):
Acute Leukemia

Connect. Empower. Inspire.